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ABSTRACT
Dementia with Lewy bodies is one of the most
common causes of dementia. It is not as common
as Alzheimer’s disease; the general public’s
awareness of the disease is poor in comparison. Its
effects on caregivers and patients alike are not well
known to the general population. There are cur-
rently no FDA-approved medications specifically
for the treatment of DLB. Many of the medica-
tions that are approved for Alzheimer’s disease are
widely used in the treatment of DLB with varying
degrees of success. Treatment of DLB is life long
and requires a dedicated team of physicians and
caregivers to minimize the degree of morbidity
and mortality experienced by the patients suffer-
ing from the disease as it progresses.
Keywords: Alpha-synuclein; Dementia;
Dementia with Lewy bodies; Lewy body
dementia
INTRODUCTION
Dementia is defined as measurable cognitive
impairment in conjunction with an impact on
activities of daily living. It encompasses a broad
constellation of conditions including neurode-
generative disease. Dementia often includes dif-
ficulty with language, memory, impulsivity, and
communication and additionally can lead to
changes in behavior and mood. Dementia with
Lewy bodies is one of several neurodegenerative
diseases that can lead to dementia and its associ-
ated symptoms in patients. Patients who are
diagnosed with dementia with Lewy bodies often
have no family history of the disease. The disease
is caused by an accumulation of alpha-synuclein
protein within neurons in the brain; these protein
aggregates are known as Lewy bodies [1].
Incidence/Prevalence
In 2002, it was estimated that 3.4 million peo-
ple in the USA over the age of 71 years had
dementia of some kind. Increasing age is the
most significant risk factor for developing
dementia; prevalence increases from 5.0% in
the age range of 71–79 to 37.4% in those aged
90 or older [2]. Alzheimer’s disease is the most
common cause of dementia in the USA.
Dementia with Lewy bodies and vascular
dementia are widely considered to be the most
prevalent causes of dementia after Alzheimer’s
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[2–4]. As the proportion of the population that
is elderly increases, proper prevention and
treatment of dementing conditions are imper-
ative because of the wide-ranging implications
for patients and caregivers alike. The incidence
of DLB is strongly associated with increasing age
and male gender. The difference in incidence
between men and women is not currently
explained but may be due to endocrine, genetic,
environmental, and other factors [5]. Histori-
cally, the diagnosis of DLB has been con-
founded because of lack of consensus on
diagnostic criteria as well as its similarities to
other dementing conditions. Thanks to new
criteria that aid identification, the incidence of
DLB has been found to account for approxi-
mately 1 out of 25 new diagnoses of dementia
in the general population. In secondary care,
DLB accounts for 1 out of 13 new diagnoses of
dementia—this is likely due to greater aware-
ness of diagnostic criteria among specialists [3].
Morbidity/Mortality
Dementia with Lewy bodies has significant
implications for the health and well-being of
patients. Outcomes in patients who suffer from
DLB are poor, particularly when contrasted with
patients who have AD. Patients with DLB have
more neuropsychiatric features at initial pre-
sentation as well as follow-up than patients
with AD. The risk of hospitalization or death
due to adverse events such as falls and respira-
tory infections is greater in DLB than AD.
Despite the differences in the frequency of
adverse events, reviews have shown there is
little difference in the rate of decline of cogni-
tive and neuropsychiatric function among vas-
cular dementia, AD, and DLB [6, 7]. Median age
at death is similar between AD and DLB; how-
ever, the time from diagnosis to death is shorter
in DLB than AD. This may be partially explained
by a delay in diagnosis of DLB. This exemplifies
the importance of refined and accurate diag-
nostic criteria for DLB. Survival time from pre-
sentation of symptoms as well as from
presentation to psychiatric services is similar
between DLB and AD patients [8]. The envi-
ronment has been observed to have an effect on
the mortality of patients who suffer from DLB.
Mortality risk in DLB patients is particularly
increased compared with Alzheimer’s disease
patients in a nursing home setting [9]. Patients
with DLB have limited mobility and rely heavily
upon caregivers to prevent falls and other
injuries. Without active caregivers, complica-
tion rates in DLB patients are high. Additional
factors that can expedite mortality in DLB
include: neuroleptic sensitivity, potentially
higher rates of hospitalization due to delirium/
encephalopathy, and higher rates of orthostatic
hypotension/autonomic dysfunction.
Impact
The impact of dementia is not limited to the
patients. The financial impact of DLB on patients
and caregivers tends to increase as the disease
progresses [10]. Besides financial concerns, care-
givers have reported on surveys that they have
fears of the future excessive stress, loss of a social
life, and uncertainty about what to do next. Many
caregivers report feelings of isolation, and no one
can understand the responsibility that they have.
A valuable tool that many caregivers of patients
with dementia utilize is respite care or hired in-
home assistance. However, only a minority of
caregivers have been found to utilize these ser-
vices to help them care for their loved ones who
have DLB [11]. Patients who suffer from DLB have
loss of independence early on in the course of
their disease, including reliance on caregivers to
complete activities of daily living [12]. Quality of
life is adversely affected in DLB: compared with
their peers who suffer from Alzheimer’s disease,
DLB patients have been found to have greatly
reduced quality of life measurements on assess-
ment regardless of whether or not quality-of-life
assessments were performed by caregivers or
patients. Delusions and apathy, common in
patients with DLB, are strongly correlated with
diminished quality of life [13]. Establishing a
diagnosis for DLB can be difficult, despite the
advent of new diagnostic criteria. The diagnostic
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process of DLB is often frustrating for caregivers
and patients alike. Half of the caregivers of
patients from a web-based survey reported seeing
over three doctors for more than ten visits before
the diagnosis of DLB was established. While neu-
rologists were reportedly responsible for 62% of
these diagnoses, primary care physicians were
only responsible for 6%. This provides evidence
for a disproportionate misunderstanding of the
diagnostic criteria, or lack of recognition, among
primary care physicians compared with specialists
[14]. The importance of making a correct diag-
nosis in degenerative dementia is crucial to
patient outcomes. Objective measurements of
diseaseburdenshowthatdiagnosisofDLB leads to
a three-fold increase in resource utilization in
addition to the significantly lower reported qual-
ity of life compared with a diagnosis of Alzhei-
mer’s disease [13].
The aim of the current study is to provide an
overview of the current diagnosis, treatment,
and investigational work being conducted in
patients with DLB. This article is based on pre-
viously conducted studies and does not contain
any studies with human participants or animals
performed by any of the authors.
RECOGNITION/DIAGNOSIS
Neuropathology
The clinical symptoms of dementia with Lewy
bodies can often overlap with those of Alzhei-
mer’s and Parkinson’s diseases. It is important
to note that mixed pathology cases commonly
occur; in certain studies distinguishing features
of both DLB and AD have been seen in up to
half of research patients at autopsy [15]. Lewy
bodies, the hallmark brain histopathology of
DLB, are not specific to DLB. These protein
aggregates are also found in other diseases
including multiple systems atrophy and
Parkinson’s disease. A key histopathologic dif-
ference in these conditions is the distribution of
these alpha-synuclein aggregates. In Parkinson’s
disease, they are found primarily within the
dopaminergic neurons of the substantia nigra
within the brainstem. In DLB, the Lewy bodies
are diffusely distributed throughout the cortices
of the brain [16]. Another key difference in
neuropathology between Parkinson’s and DLB
is the microscopic appearance of these Lewy
bodies: the cortically distributed Lewy bodies of
DLB are less eosinophilic, less distinctly
demarcated, and less filamentous than those of
the Lewy bodies of the brainstem in PD [17].
Lewy bodies have been found in familial AD,
AD associated with Down’s syndrome, and
sporadic AD, most commonly restricted to the
amygdala [18]. There is some thought that, due
to the heterogeneous nature of the deficiencies
in neurotransmitters associated with Alzhei-
mer’s disease, DLB and other neurodegenerative
diseases, they represent a spectrum of disease
rather than solitary and distinct conditions.
Skeptics argue that, due to the varying presen-
tation of Lewy body disease among affected
patients, it is possible that DLB is just a sub-
population suffering from an already known
and recognized disease possessing uniquely
differentiating characteristics (e.g., neuroleptic
sensitivity) [19]. While it is important to con-
sider similarities between the various neurode-
generative disorders and the likelihood of
mixed pathology cases, current understanding
of the available literature requires clinicians to
utilize a similar but individually tailored
approach to treatment of patients with these
different diagnoses. Finally, this heterogeneous
pathologic milieu may also have implications
for the targeted approach of current experi-
mental treatments of these conditions and
likely implies a need for in vivo characterization
and tailored multifaceted approaches.
Clinical Features
Lewy body dementia is an umbrella term that
encompasses both Parkinson’s disease dementia
and DLB. In a clinical setting, it may be difficult
to distinguish between DLB and Parkinson’s
disease dementia if the temporal relationship
between symptoms has not been well docu-
mented. Generally the onset of dementia and
parkinsonism occurs concurrently in DLB. In
research, applying a 1-year rule between the
onset of parkinsonism and dementia can help
distinguish between DLB and Parkinson’s
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disease dementia [20]. In contrast, the mean
duration of Parkinson’s symptoms prior to
dementia in Parkinson’s disease dementia is
10 years [21]. The Consortium on Dementia
with Lewy Bodies recommendations and con-
sensus criteria have recently been revised and
improved. These changes were put in place with
the goal of increased sensitivity in the detection
of the disease in the hopes of improving on
what was previously seen as unsatisfactory
accurate diagnosing of patients suffering from
DLB [3, 20]. Diagnosis of DLB depends on the
presence of core clinical features in the setting
of a progressive dementia, which often has
cognitive deficits in attention, executive func-
tioning, and visuospatial abilities. The core
clinical features, supportive clinical features,
core (indicative) biomarkers, and supportive
biomarkers are included in Table 1. Diagnosis of
DLB can be further differentiated between
‘‘probable’’ and ‘‘possible’’ diagnosis. ‘‘Probable’’
DLB can be diagnosed if (in addition to
dementia) either two of the core clinical fea-
tures are present with or without the presence
of indicative biomarkers or only one core clin-
ical feature is present alongside one or more of
the indicative biomarkers. ‘‘Possible’’ DLB can
be diagnosed if only one core clinical feature of
DLB is present with no indicative biomarkers or
if one or more of the indicative biomarkers are
present but there are no core clinical features
[20].
Dementia is the essential hallmark symptom
of DLB. Dementia by definition must be severe
enough to interfere with a patient’s day-to-day
functioning, often interfering with occupa-
tional and social activities. Screening tests such
as the Mini-Mental State Examination (MMSE)
and Montreal Cognitive Assessment (MOCA)
have utility in screening a patient’s overall
mentation and impairment. These tests alone
may not be adequate in establishing a conclu-
sive neurocognitive assessment in DLB patients.
A thorough assessment for DLB involves in
depth testing of the most commonly affected
domains of cognition including visual process-
ing, attention, and executive function. In con-
trast to early memory impairment of AD,
memory impairment of DLB is not an early
prominent feature, instead appearing later in
the course of the disease [17]. Comparisons of
cognition between DLB versus AD and DLB
versus normal controls have shown significant
deficits in attention/concentration, visual per-
ception/construction, naming, letter fluency,
and verbal memory in the DLB groups. In dis-
tinguishing between patients with DLB and AD,
particular attention should be paid to trail-
making tests and complex figure copying. Both
AD and DLB patients have impairments in
attention and visual perception/construction
tests compared with normal controls. However,
DLB patients have impairments to a much
greater extent [22]. Fluctuations in cognition
are a core clinical feature of DLB. These fluctu-
ations are most useful in distinguishing DLB
early in the course of the disease. The qualita-
tive features of the cognition fluctuations in
DLB are generally regarded as their distin-
guishing feature compared with the cognitive
fluctuations of other dementing conditions.
Studies that assess caregiver perceptions of
cognition fluctuations provide descriptions
such as episodes of ‘‘blank staring’’ or disen-
gagement in DLB in contrast to the episodes of
confusion (such as repetition of conversation or
task-based/situational confusion) common to
AD. Episodic confusion in DLB patients has
been observed to have confabulatory or delu-
sional qualities as well. Additionally, daytime
somnolence is reported more frequently among
caregivers of DLB patients. Cognitive fluctua-
tions regardless of description have been shown
to be more frequent in DLB patients than in
those with AD [23].
Visual hallucinations are prevalent in
patients who suffer from DLB, occurring in up
to 80% of patients. These hallucinations are
often described as people, children, or animals.
Other visual perceptive symptoms such as
flashing lights, visual patterns, and shadows
have been reported. Patients may respond to
these hallucinations with varying degrees of
insight and emotional reaction [20]. Visual
hallucinations at initial presentation have a
very strong positive predictive value for a diag-
nosis of dementia with Lewy bodies (and lack of
visuospatial impairment being the best negative
predictor for the disease) [24]. The presence of
early, severe visuospatial deficits is a good
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indicator for the development of visual hallu-
cinations. DLB patients who have severe visu-
ospatial deficits early on in the course of their
disease are more likely to develop these visual
hallucinations than patients with more mild
deficits [25]. Clinical observation or reporting
on thorough history taking of visual hallucina-
tions and generalized visuospatial impairments
are very important for the differentiation
between DLB and AD. Like visual hallucina-
tions, auditory and tactile hallucinations have
been reported in patients with DLB to varying
degrees, although to a lesser extent [26]. These
hallucinations can occasionally lead to episodes
of disabling psychosis; however, caregivers
should exercise caution in the use of neurolep-
tic medications.
Neuroleptic sensitivity is a widely recognized
feature of DLB. Reactions to neuroleptics in
these patients can include paradoxical agita-
tion, increases in parkinsonian motor and
extrapyramidal symptoms, and neuroleptic
malignant syndrome. Severe neuroleptic sensi-
tivity in DLB patients has been observed to be
associated with increased mortality and mark-
edly decreased survival time from onset of
Table 1 Diagnostic criteria for dementia with Lewy bodies Adapted from McKeith et al. [20]
Essential feature Diagnosis of dementia with progressive decline and often with features of impaired
executive functioning, visuospatial abilities, and attention
Core clinical features Fluctuations in cognition with pronounced changes in attention/alertness
Recurrent visual hallucinations
REM behavior disorder
One or more spontaneous cardinal features of parkinsonism
Supportive clinical
features
Neuroleptic sensitivity
Postural instability
Repeated falls
Syncope or episodes of unresponsiveness
Autonomic dysfunction
Hypersomnia
Hyposmia
Hallucination in other modalities
Delusional thoughts
Apathy
Anxiety/depression
Core (indicative)
biomarkers
Reduced dopamine transporter uptake on SPECT/PET
Low uptake on 123iodine-MIBG myocardial scintigraphy
Polysomnographic evidence of REM sleep without atonia
Supportive biomarkers MRI with relative preservation of mesial temporal lobe structures
SPECT/PET with generalized low uptake and reduced occipital activity
EEG with prominent slow wave activity and fluctuations into pre-alpha/theta range
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psychiatric symptoms compared with other
types of dementia [27]. Treatment with first
generation neuroleptics portends higher risk of
reaction than atypical (second generation)
neuroleptics. Low doses of atypical neuroleptics
may sometimes be used in treatment if hallu-
cinations are having a major impact on quality
of life.
Parkinsonian motor symptoms are common
in DLB, with up to 85% of patients experiencing
them [20]. Motor symptoms of DLB patients are
similar to PD patients. These symptoms pri-
marily include rest tremor, bradykinesia, mus-
cular rigidity, and axial instability/gait
disturbance. In the authors’ clinical experience,
rest tremor is less prevalent in DLB than in
idiopathic Parkinson’s disease, and this is also
supported by some limited published data [28].
Another study showed more bradykinesia, more
severe action tremor, and more rigidity than in
idiopathic Parkinson’s patients [29]. This
implies that factors other than nigral cell loss
may contribute to EPS symptoms in DLB
patients.
REM sleep behavior disorder is a commonly
reported core clinical feature of DLB. REM sleep
behavior can precede DLB by many years and,
in some cases, even decades [30–32]. Among
REM sleep behavior disorder patients, cognitive
tests that evaluate executive functions and
attention have been shown to reliably predict
eventual development of dementia [33].
Patients with DLB who have probable REM sleep
behavior disorder also have been found to have
earlier and more rapid onset of the core clinical
features of DLB, including parkinsonism and
hallucinations [34]. Polysomnography may be
helpful to definitively diagnose REM sleep
behavior disorder and rule out other etiologies
of sleep disturbance among DLB patients and is
one of the core (indicative) biomarkers.
Dysautonomia, while not generally consid-
ered a core clinical feature of dementia with
Lewy bodies, is a supportive feature in the
diagnosis of the disease. Symptoms of auto-
nomic dysfunction include orthostatic
hypotension, tachycardia, incontinence, and
constipation [20]. This dysautonomia in
patients with DLB is associated with shorter
survival. The symptom of dysautonomia that is
most closely correlated to decreased survival is
orthostatic hypotension; the symptoms of
constipation and incontinence are obviously
disabling, but are not particularly specific to
autonomic dysfunction as they are common in
the elderly populations [35]. Delusional
thoughts can occur in DLB with the most
common delusion being Capgras syndrome. In
this syndrome, the patient believes that his
loved one is an ‘‘imposter.’’ Clinically, patients
will often question their spouse and ask where
their spouse is. They will ask ‘‘are we married?’’
They may recognize that there are multiple
copies of their spouse and can either name or
designate which version of their spouse is pre-
sent. In the clinical experience of the authors,
Capgras is the most common delusion, and it is
more prevalent in DLB than in other types of
dementia.
Biomarkers/Imaging
Biomarkers can be helpful in the diagnostic
process of DLB. The diagnosis of probable DLB
can be made if one or more of the indicative
biomarkers is associated with one or more of the
aforementioned core clinical features. If
dementia is present in the absence of core
clinical features but with one or more of the
indicative biomarkers, probable DLB is instead
diagnosed [20]. Low dopamine transporter
reuptake in the basal ganglia shown by SPECT
or PET imaging is a now widely accepted
indicative biomarker for probable DLB. Sensi-
tivity for DLB diagnosis with one of these scans
has been shown to be 78%, with a specificity of
90% for excluding non-DLB dementia (primar-
ily AD). This can be helpful in differentiation
between DLB and AD [36]. Reduced uptake of
123iodine-MIBG on myocardial scintigraphy is
another widely accepted indicative biomarker
for DLB. Further decreased uptake of 123iodine-
MIBG has been shown to correlate with
increased severity of cognitive impairments
between patients with severe impairments
compared with those with mild or moderate
impairments, as well as between patients with
and without orthostatic hypotension [37]. 123I-
MIBG myocardial scintigraphy has also been
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shown to reliably predict conversion to proba-
bly DLB from possible DLB [38]. 123I-MIBG
myocardial scintigraphy is more widely avail-
able in Europe and less available in the US. A
third indicative biomarker for DLB is the pres-
ence of distinctive polysomnographic findings
showing REM sleep that occurs without atonia.
One retrospective study over an 11-year period
of DLB patients who underwent PSG showed
96% experienced REM sleep without atonia
[39].
Supportive biomarkers have been found to
be consistent with the diagnosis of DLB, but
their diagnostic specificity for the condition is
not entirely clear. For this reason, they are not
considered in the diagnosis of probable or pos-
sible DLB [20]. In most practices, and according
to the American Academy of Neurology practice
parameter for dementia [40], MRI or CT scans of
the brain are routinely obtained in patients with
suspected DLB. Certain findings on the struc-
tural neuroimaging can be supportive in the
diagnosis. Unlike AD patients, DLB patients
have been found to have minimal atrophy of
their medial temporal lobes on brain imaging.
This temporal lobe atrophy has been found to
be more consistent with the tangle
histopathology of AD than with the diffuse
Lewy body histopathology of DLB [41]. SPECT
and PET scans serve as additional supportive
biomarkers for DLB when there are signs of
generalized decreased perfusion/metabolism in
patient brains, particularly when they are in the
occipital region. SPECT perfusion measurement
of cerebral blood flow using 99mTc-hexam-
ethylpropyleneamine oxime (99mTc-HMPAO)
has been shown to have 65% sensitivity and
87% specificity for DLB diagnosis against AD
[42]. Brain imaging of metabolic function with
glucose (18F-FDG) PET scanning has been shown
to be superior to 99mTc-HMPAO perfusion
scanning for accurate distinction between DLB
and AD, with a sensitivity of 70% and a speci-
ficity of 74% [43]. Despite their utility in dis-
tinguishing between AD and DLB in research,
these tests do not have proven accuracy at the
levels necessary to be considered as indicative
biomarkers in the new diagnostic criteria for
DLB [20]. EEG is not routinely used in the
diagnosis of dementia, but has displayed utility
in differentiation between DLB and AD when
practitioners need additional data to distinguish
between the two clinically. EEG in DLB patients
has shown theta/delta waves in posterior and
anterior/temporal deviations, as opposed to a
majority of AD patients showing alpha waves in
posterior deviations [44]. Genetics and fluid
studies do not currently have any established
utility in the diagnosis of DLB. Genome-wide
association studies of patients who suffer from
DLB, utilizing genotyping arrays, showed asso-
ciations among the APOE, SNCA, GBA, BCL7C/
STX1B, and GABRB3 loci and a positive diag-
nosis of DLB. Interestingly, the APOE locus has
previously been shown to be associated with
diagnoses of DLB and AD. This same study
estimated the heritability of a diagnosis of DLB
to be about 36% [45]. CSF studies may be
helpful in distinguishing between DLB and
other forms of dementia. The CSF of patients
with DLB, like patients with AD, often contains
increased amounts of tau protein. Higher con-
centrations of CSF tau have been correlated
with earlier mortality in DLB patients [6]. Mea-
surements of Ab peptide in CSF has been shown
to be different in patients suffering from a-
synucleinopathies from control patients. One
such study showed that CSF levels of Ab1-42 in
DLB patients were decreased compared with
patients who served as non-demented controls.
This is similar to what has been seen in com-
parisons between AD patients and non-de-
mented controls [46].
TREATMENT/MANAGEMENT
No cure or disease-modifying treatment for
dementia with Lewy bodies exists. Treatment of
dementia with Lewy bodies is complex and
requires a team of multidisciplinary caregivers.
The goal of treatment is to relieve the burdens
posed by the many symptoms of the disease in
addition to educating patients and caregivers
about what to expect during the course of the
disease. The pharmacologic interventions used
for treatment of the disease potentially slow
progression but do not stop it. Care of DLB
patients requires using appropriate interven-
tions (pharmacologic and non-pharmacologic)
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that are life-long and require adjustment to
maintain optimal care throughout disease pro-
gression. Although there are no medications
currently FDA approved for the treatment of
dementia with Lewy bodies, medications cur-
rently used in the treatment of DLB have sig-
nificant overlap with those that are FDA
approved for the treatment of Alzheimer’s dis-
ease. When considering the use of medication
in DLB treatment, the medical benefits must be
weighed against possible adverse effects from
the use of these medications.
Cholinesterase Inhibitors
Cholinesterase inhibitors are one of the main
pharmacologic treatments for dementia with
Lewy bodies. They have been extensively stud-
ied for the treatment of Alzheimer’s disease. The
function of these pharmacologic agents is to
increase the levels of acetylcholine within the
brain, as acetylcholine is crucial to the mainte-
nance of cognitive functions. Choline acetyl-
transferase, an important enzyme in the
synthesis of acetylcholine, has been found to be
more deficient in patients with DLB than in
patients with Alzheimer’s disease [47]. This
cholinergic deficiency is thought to contribute
to the neuropsychiatric symptoms of DLB.
Cholinesterase inhibitors have shown efficacy
in the improvement of cognitive functions of
patients diagnosed with DLB. Many cholines-
terase inhibitors are available for use in DLB;
these include donepezil, rivastigmine, and
galantamine. A comparative analysis of the
three showed global improvement of cognitive
and neuropsychiatric measures in DLB patients
with their use; none of the three were found to
have greater efficacy than the others [48].
Donepezil appears to be the most well studied
and widely used of the cholinesterase inhibitors
in the treatment of DLB. It was approved in
2014 for the treatment of DLB in Japan [49]. In
randomized controlled trials, when compared
with placebo, donepezil has been shown to
improve mental status [50] and overall behav-
ioral, cognitive, and global function in patients
with DLB [51, 52]. In patients where donepezil
is well tolerated at a lower dose without adverse
effects, increasing the dose from 5 to 10 mg/day
can improve cognitive function further [51.
Multicenter open-label studies have proven the
long-term safety of donepezil for the treatment
of psychiatric and cognitive function [53]. One
review of the available literature has shown that
the use of donepezil in patients with DLB is
effective in the treatment of neuropsychiatric
symptoms [54]. Donepezil has been shown be
relatively safe to use in patients with DLB
without exacerbating existing extrapyramidal
symptoms in long-term use [55]. Rivastigmine,
another acetylcholinesterase inhibitor used in
DLB, has shown efficacy in randomized con-
trolled trials for treatment of DLB compared
with placebo [56]. It is FDA approved for the
treatment of mild-to-moderate Parkinson’s dis-
ease dementia, which by definition is a type of
Lewy body dementia [57]. Galantamine, a third
acetylcholinesterase inhibitor used in DLB, has
been investigated extensively for the treatment
of Alzheimer’s disease. However, no random-
ized controlled trials have been completed for
galantamine in the treatment of DLB. An open-
label investigation of galantamine showed sig-
nificant improvement in cognitive deficits and
visual hallucinations in DLB patients who were
treated with the medication after 24 weeks [58].
In the authors’ clinical experience, treatment of
DLB with cholinesterase inhibitors leads to a
more profound clinical response than treatment
of AD patients. Observed responses include
decreased hallucination, decreased fluctuations,
and increased alertness. With donepezil, doses[
10 mg (often 10 mg in the morning after a meal
and 5 mg after the evening meal) are considered
if tolerated because of the clinical response.
Memantine
Memantine, a glutamatergic NMDA receptor
antagonist, may be useful in the treatment of
DLB. However, research on the therapeutic
effects of memantine is limited. Randomized
controlled studies have shown moderate clini-
cal improvement in the use of memantine in
DLB versus placebo [59, 60]. A small-scale
prospective randomized controlled trial has
shown that compared with placebo memantine
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can improve the survival of DLB patients if
initiated early on in the course of the disease
[61]. In the authors’ practice, it is not routinely
used because of the lack of substantial clinical
evidence, but can be considered.
Levodopa
The parkinsonism symptoms that may be pre-
sent in patients with DLB can be managed
similarly to the symptoms of idiopathic
Parkinson’s disease. DLB patients who suffer
from parkinsonian movement symptoms can be
treated with levodopa. Levodopa is preferred to
dopamine agonists for the treatment of symp-
toms of parkinsonism in DLB. Dopamine ago-
nists have been found to have greater potential
for worsening neuropsychiatric symptoms such
as hallucinations, confusion, and psychosis
with less benefit in motor control than levo-
dopa [27]. However, the responsiveness of these
motor symptoms to levodopa is much less than
the motor symptoms in patients with Parkin-
son’s disease or Parkinson’s disease dementia
[62]. Extended follow-up of patients with DLB
compared with AD who are treated with levo-
dopa has yielded the same results. This shows
that chronic long-term use of levodopa in DLB
patients can yield a positive response in their
motor symptoms, but not to the same extent as
their peers with AD [63]. In the clinical practice
of the authors, low doses of carbidopa/levodopa
are often well tolerated, but moderate and high
doses can precipitate worsening of hallucina-
tions and should be used with caution.
Neuroleptics
Neuroleptics must be used with great caution in
dementia with Lewy bodies. As stated previ-
ously, patients who suffer from DLB are known
to have a very high sensitivity to the side effects
of these medications [27]. Neuroleptics can
exacerbate many of the symptoms associated
with DLB, including cognitive fluctuations,
motor symptoms, and dysautonomia. First
generation antipsychotics should be avoided
entirely in all patients with DLB. The authors
often list a drug ‘‘allergy’’ to haloperidol in
electronic medical records of patients who are
diagnosed with DLB to further disincentivize
the use of these drugs if a patient is hospitalized.
If treatment of disturbing hallucinations or
delusions is deemed necessary based on a major
impact on patient quality of life, priority should
be considered for quetiapine, which has the
lowest incidence of extrapyramidal symptoms.
A case series provided limited evidence for the
use of quetiapine in DLB patients. Five of nine
patients were found to have a positive response
in a reduction of their psychotic symptoms and
agitated behavior when treated with quetiapine
[64]. The atypical antipsychotic olanzapine has
been studied in patients with DLB. Randomized
controlled trials of olanzapine in patients with
DLB have produced mixed results. One RCT
showed that the medication had little utility in
the treatment of DLB [65], while another RCT
showed that olanzapine was capable of reducing
psychosis in DLB patients with worsening of
their parkinsonian symptoms [66].
Other Treatments
REM sleep behavior disorder can be treated if
this impacts patient or caregiver quality of life.
The first-line therapy is typically to use mela-
tonin at bedtime. Doses up to 15 mg may be
required. If melatonin is unsuccessful, clon-
azepam can be used to treat severe REM sleep
behavior disorder. Hypersomnolence associated
with DLB was been shown to be responsive to
pharmacotherapy in a small study. A 12-week
open-label pilot study of the psychostimulants
modafinil and armodafinil has yielded some
positive results. Improvement of several assess-
ments related to wakefulness was observed with
these therapeutic agents. Caregiver quality of
life was shown to improve as well [67]. Non-
pharmacologic interventions have been shown
to have benefit in the management of patients
who suffer from DLB. A systematic review of the
literature on non-pharmacologic interventions
found particular benefit in exercise therapy,
physical therapy, patient/caregiver education,
music therapy, occupational therapy, and
interventions to prevent aspiration in patients
with dysphagia [68].
Neurol Ther (2018) 7:249–263 257
Future Pharmacologics and Clinical Trials
Clinical trials specifically for the treatment of
DLB have only begun in the USA in the last
2 years. The first interventional clinical trials for
DLB were started by Axovant Sciences Corp.
They began by developing two novel therapeu-
tics known as intepirdine and nelotanserin.
Intepirdine is a selective 5-HT6 receptor antag-
onist. The HEADWAY-DLB Study was a double-
blind, placebo-controlled study to assess inte-
pirdine’s efficacy in reducing parkonsonian
symptoms and improving cognitive symptoms
as well as caregiver’s interpretation of change
and occurrence of adverse events evaluated by
investigators. An additional trial to assess inte-
pirdine’s effect on gait was also completed.
Unfortunately, preliminary results made
recently available have shown that intepirdine
made no significant difference compared with
placebo for all study endpoints. While inte-
pirdine was generally well tolerated in these
studies, neither 35 mg nor 70 mg of intepirdine
was found to make a significant difference in
motor function, cognition, global function, or
gait impairment [69–71].
Nelotanserin is a second novel therapeutic
undergoing clinical trials as a treatment for
DLB. Nelotanserin is an inverse agonist of
serotonin receptors of the subtype 5-HT2A.
Randomized clinical trials are ongoing to assess
nelotanserin’s safety and tolerance based on the
incidence of adverse effects. These ongoing
randomized-clinical trials are also observing
changes in extrapyramidal symptoms and fre-
quency of visual hallucinations; an open-label
study is ongoing as well. Results are not yet
available from these studies but prespecified
analyses of the DLB patient subset have shown
improvement in parkinsonian symptoms [a
4.00-point improvement in the Unified Parkin-
son’s Disease Rating Schedule (p = 0.041,
unadjusted)] when nelotanserin was compared
with placebo. In patients with a baseline Scale
for the Assessment of Positive Symptoms[8.0,
nelotanserin treatment at 40 mg for 2 weeks
followed by 80 mg for 2 weeks led to a 1.21
point improvement (p = 0.011, unadjusted).
However, this improvement was not observed
in the entire evaluable population. Nelotanserin
was also generally well tolerated in the patients
involved [72–74].
Several other companies have begun inter-
ventional clinical trials for DLB. Eli Lilly and Co.
are openly recruiting for the Presence Study for
patients with Parkinson’s disease dementia and
DLB [75]. This phase 2 study will be using a
dopamine D1 receptor potentiator to look at a
cognitive primary end point. Eisai, a Japanese
pharmaceutical company and the maker of
donepezil (Aricept), plans to open a phase 2
study for its drug E2027, a selective phospho-
diesterase-9 inhibitor, in DLB patients [76]. This
study will also pursue a cognitive end point.
Stem Cell Therapy
Stem cell therapy has been hypothesized as a
treatment modality for DLB. Researchers devel-
oped an immune-deficient transgenic DLB
murine model that exhibited progressive accu-
mulation of human alpha-synuclein inclusions
as well as cognitive and motor impairments,
similar to that of patients suffering from DLB.
Following grafts of human neural progenitor
cells (CNS10-hNPCs), behavior assessments of
the experimental murine model were com-
pleted at 30 and 90 days. Transplantation of
these cells was found to rescue motor and cog-
nitive deficits among the experimental murine
model. Restoration of dopaminergic and gluta-
matergic regulation was additionally observed
[77]. Although these animal study results are
promising, clinical translation of these human
neural progenitor cells may be complicated by
the fact that immunosuppressive medications
such as tacrolimus have been shown to modu-
late alpha-synuclein pathology [78].
CONCLUSIONS
While a great deal of progress has been made in
the accurate diagnosis and effective treatment
of DLB, important developments are still
ongoing. Translational research activities
developing new treatments for DLB are ongo-
ing, and it will take time to understand the
clinical impact. Raising awareness about DLB
among the general population and physicians
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continues to be an important goal among
advocates of DLB patients. Diagnosis of the
disease is primarily clinical and requires primary
care, specialty physicians and caregivers to
remain vigilant for the early manifestations of
DLB. It is the responsibility of the medical
community to make the resources necessary for
disease management available to patients and
caregivers when faced with a diagnosis as
daunting as DLB.
ACKNOWLEDGEMENTS
Funding. No funding or sponsorship was
received for this study or publication of this
article.
Authorship. All named authors meet the
International Committee of Medical Journal
Editors (ICMJE) criteria for authorship for this
manuscript, take responsibility for the integrity
of the work as a whole, and have given final
approval to the version to be published.
Disclosures. Samuel Capouch has nothing
to disclose. Martin Farlow has received grant/
research support from AbbVie, Accera, Axovant,
Avanir, Biogen, Boehringer Ingelheim, Domi-
nantly Inherited Alzheimer Network, Eisai, Eli
Lilly, Genentech, Lundbeck, Novartis, Roche,
and Suven Life Sciences, Ltd. He is part of the
Consultant/Advisory Boards/DSMB Boards for
Accera, Avanir, Axovant, AZTherapies, Cogni-
tion Therapeutics, Eli Lilly & Co., FORUM
Pharmaceuticals Inc. Research, KCRN Research,
Kyowa Kirin Pharma, Longeveron, Medavante,
Merck and Co. Inc., Proclara (formerly Neu-
rophage Pharmaceuticals), Neurotrope Bio-
sciences, Stemedica Cell Technologies Inc.,
Takeda, United Neuroscience Inc., and vTv
Therapeutics. He is also affiliated with Elan.
Jared R. Brosch has received grant/research
support from AbbVie, Accera, Axovant, Avanir,
Biogen, Boehringer Ingelheim, Dominantly
Inherited Alzheimer Network, Eisai, Eli Lilly,
Genentech, Lundbeck, Novartis, Roche, and
Suven Life Sciences, Ltd.
Compliance with Ethics Guidelines. This
article is based on previously conducted studies
and does not contain any studies with human
participants or animals performed by any of the
authors.
Open Access. This article is distributed
under the terms of the Creative Commons
Attribution-NonCommercial 4.0 International
License (http://creativecommons.org/licenses/
by-nc/4.0/), which permits any non-
commercial use, distribution, and reproduction
in any medium, provided you give appropriate
credit to the original author(s) and the source,
provide a link to the Creative Commons license,
and indicate if changes were made.
REFERENCES
1. Spillantini MG, Schmidt ML, Lee VM, Trojanowski
JQ, Jakes R, Goedert M. Alpha-synuclein in Lewy
bodies. Nature. 1997;388(6645):839–40.
2. Plassman BL, Langa KM, Fisher GG, Heeringa SG,
Weir DR, Ofstedal MB, et al. Prevalence of dementia
in the United States: the aging, demographics, and
memory study. Neuroepidemiology.
2007;29(1–2):125–32.
3. Vann Jones SA, O’Brien JT. The prevalence and
incidence of dementia with Lewy bodies: a sys-
tematic review of population and clinical studies.
Psychol Med. 2014;44(4):673–83.
4. McKeith IG, Galasko D, Kosaka K, Perry EK, Dickson
DW, Hansen LA, et al. Consensus guidelines for the
clinical and pathologic diagnosis of dementia with
Lewy bodies (DLB): report of the consortium on
DLB international workshop. Neurology.
1996;47(5):1113–24.
5. Savica R, Grossardt BR, Bower JH, Boeve BF, Ahlskog
JE, Rocca WA. Incidence of dementia with Lewy
bodies and Parkinson disease dementia. JAMA
Neurol. 2013;70(11):1396–402.
6. Mayo MC, Bordelon Y. Dementia with Lewy bodies.
Semin Neurol. 2014;34(2):182–8.
7. Breitve MH, Chwiszczuk LJ, Hynninen MJ, Rongve
A, Bronnick K, Janvin C, et al. A systematic review
of cognitive decline in dementia with Lewy bodies
versus Alzheimer’s disease. Alzheimers Res Ther.
2014;6(5–8):53.
Neurol Ther (2018) 7:249–263 259
8. Walker Z, Allen RL, Shergill S, Mullan E, Katona CL.
Three years survival in patients with a clinical
diagnosis of dementia with Lewy bodies. Int J
Geriatr Psychiatry. 2000;15(3):267–73.
9. Zweig YR, Galvin JE. Lewy body dementia: the
impact on patients and caregivers. Alzheimers Res
Ther. 2014;6(2):21.
10. Ku LJ, Pai MC, Shih PY. Economic impact of
dementia by disease severity: exploring the rela-
tionship between stage of dementia and cost of care
in Taiwan. PLoS One. 2016;11(2):e0148779.
11. Galvin JE, Duda JE, Kaufer DI, Lippa CF, Taylor A,
Zarit SH. Lewy body dementia: caregiver burden
and unmet needs. Alzheimer Dis Assoc Disord.
2010;24(2):177–81.
12. Williams MM, Xiong C, Morris JC, Galvin JE. Sur-
vival and mortality differences between dementia
with Lewy bodies vs Alzheimer disease. Neurology.
2006;67(11):1935–41.
13. Bostrom F, Jonsson L, Minthon L, Londos E.
Patients with dementia with lewy bodies have more
impaired quality of life than patients with Alzhei-
mer disease. Alzheimer Dis Assoc Disord.
2007;21(2):150–4.
14. Galvin JE, Duda JE, Kaufer DI, Lippa CF, Taylor A,
Zarit SH. Lewy body dementia: the caregiver expe-
rience of clinical care. Parkinsonism Relat Disord.
2010;16(6):388–92.
15. Toledo JB, Cairns NJ, Da X, Chen K, Carter D, Fle-
isher A, et al. Clinical and multimodal biomarker
correlates of ADNI neuropathological findings. Acta
Neuropathol Commun. 2013;1:65.
16. Tsuboi Y, Uchikado H, Dickson DW. Neuropathol-
ogy of Parkinson’s disease dementia and dementia
with Lewy bodies with reference to striatal pathol-
ogy. Parkinsonism Relat Disord. 2007;13(Suppl
3):S221–4.
17. Mrak RE, Griffin WS. Dementia with Lewy bodies:
definition, diagnosis, and pathogenic relationship
to Alzheimer’s disease. Neuropsychiatr Dis Treat.
2007;3(5):619–25.
18. Hamilton RL. Lewy bodies in Alzheimer’s disease: a
neuropathological review of 145 cases using alpha-
synuclein immunohistochemistry. Brain Pathol.
2000;10(3):378–84.
19. Muller T. Editorial regarding: practical treatment of
Lewy body disease in the clinic: patient and physi-
cian perspectives. Neurol Ther. 2018;7(1):1–3.
20. McKeith IG, Boeve BF, Dickson DW, Halliday G,
Taylor JP, Weintraub D, et al. Diagnosis and
management of dementia with Lewy bodies: fourth
consensus report of the DLB Consortium. Neurol-
ogy. 2017;89(1):88–100.
21. Aarsland D, Kurz M. The eidemiology of dementia
associated with Parkinson disease. J Neurol Sci.
2010;289(1–2):18–22.
22. Ferman TJ, Smith GE, Boeve BF, Graff-Radford NR,
Lucas JA, Knopman DS, et al. Neuropsychological
differentiation of dementia with Lewy bodies from
normal aging and Alzheimer’s disease. Clin Neu-
ropsychol. 2006;20(4):623–36.
23. Bradshaw J, Saling M, Hopwood M, Anderson V,
Brodtmann A. Fluctuating cognition in dementia
with Lewy bodies and Alzheimer’s disease is quali-
tatively distinct. J Neurol Neurosurg Psychiatry.
2004;75(3):382–7.
24. Tiraboschi P, Salmon DP, Hansen LA, Hofstetter RC,
Thal LJ, Corey-Bloom J. What best differentiates
Lewy body from Alzheimer’s disease in early-stage
dementia? Brain. 2006;129(Pt 3):729–35.
25. Hamilton JM, Landy KM, Salmon DP, Hansen LA,
Masliah E, Galasko D. Early visuospatial deficits
predict the occurrence of visual hallucinations in
autopsy-confirmed dementia with Lewy bodies. Am
J Geriatr Psychiatry. 2012;20(9):773–81.
26. Onofrj M, Taylor JP, Monaco D, Franciotti R,
Anzellotti F, Bonanni L, et al. Visual hallucinations
in PD and Lewy body dementias: old and new
hypotheses. Behav Neurol. 2013;27(4):479–93.
27. McKeith I, Fairbairn A, Perry R, Thompson P, Perry
E. Neuroleptic sensitivity in patients with senile
dementia of Lewy body type. BMJ.
1992;305(6855):673–8.
28. Onofrj M, Varanese S, Bonanni L, Taylor J-P,
Antonini A, Valente E, et al. Cohort study of
prevalence and phenomenology of tremor in
dementia with Lewy bodies. J Neurol.
2013;260:1731–42.
29. Aarsland D, Ballard C, McKeith I, Perry RH, Larsen
JP. Comparison of extrapyramidal signs in demen-
tia with Lewy bodies and Parkinson’s disease.
J Neuropsychiatry Clin Neurosci. 2001;13(3):374–9.
30. Boeve BF, Silber MH, Saper CB, Ferman TJ, Dickson
DW, Parisi JE, et al. Pathophysiology of REM sleep
behaviour disorder and relevance to neurodegen-
erative disease. Brain. 2007;130(Pt 11):2770–88.
31. Ferman TJ, Boeve BF, Smith GE, Silber MH, Kokmen
E, Petersen RC, et al. REM sleep behavior disorder
and dementia: cognitive differences when com-
pared with AD. Neurology. 1999;52(5):951–7.
260 Neurol Ther (2018) 7:249–263
32. Ferman TJ, Boeve BF, Smith GE, Silber MH, Lucas
JA, Graff-Radford NR, et al. Dementia with Lewy
bodies may present as dementia and REM sleep
behavior disorder without parkinsonism or hallu-
cinations. J Int Neuropsychol Soc.
2002;8(7):907–14.
33. Genier Marchand D, Montplaisir J, Postuma RB,
Rahayel S, Gagnon JF. Detecting the cognitive
prodrome of dementia with Lewy bodies: a
prospective study of rem sleep behavior disorder.
Sleep. 2017;40(1):1–11.
34. Dugger BN, Boeve BF, Murray ME, Parisi JE,
Fujishiro H, Dickson DW, et al. Rapid eye move-
ment sleep behavior disorder and subtypes in
autopsy-confirmed dementia with Lewy bodies.
Mov Disord. 2012;27(1):72–8.
35. Stubendorff K, Aarsland D, Minthon L, Londos E.
The impact of autonomic dysfunction on survival
in patients with dementia with Lewy bodies and
Parkinson’s disease with dementia. PLoS One.
2012;7(10):e45451.
36. McKeith I, O’Brien J, Walker Z, Tatsch K, Booij J,
Darcourt J, et al. Sensitivity and specificity of
dopamine transporter imaging with 123I-FP-CIT
SPECT in dementia with Lewy bodies: a phase III,
multicentre study. Lancet Neurol.
2007;6(4):305–13.
37. Chung EJ, Kim SJ. (123)I-Metaiodobenzylguanidine
Myocardial Scintigraphy in Lewy body-related dis-
orders: a literature review. J Mov Disord.
2015;8(2):55–66.
38. Oda H, Ishii K, Terashima A, Shimada K, Yamane Y,
Kawasaki R, et al. Myocardial scintigraphy may
predict the conversion to probable dementia with
Lewy bodies. Neurology. 2013;81(20):1741–5.
39. Pao WC, Boeve BF, Ferman TJ, Lin SC, Smith GE,
Knopman DS, et al. Polysomnographic findings in
dementia with Lewy bodies. Neurologist.
2013;19(1):1–6.
40. Knopman D, DeKosky S, Cummings J, Chui H,
Corey-Bloom J, Relkin N, et al. Practice parameter:
diagnosis of dementia (an evidence-based review).
Report of the quality standards subcommittee of
the American Academy of Neurology. Neurology.
2001;56(9):1143–53.
41. Burton EJ, Barber R, Mukaetova-Ladinska EB, Rob-
son J, Perry RH, Jaros E, et al. Medial temporal lobe
atrophy on MRI differentiates Alzheimer’s disease
from dementia with Lewy bodies and vascular
cognitive impairment: a prospective study with
pathological verification of diagnosis. Brain.
2009;132(Pt 1):195–203.
42. Lobotesis K, Fenwick JD, Phipps A, Ryman A, Swann
A, Ballard C, et al. Occipital hypoperfusion on
SPECT in dementia with Lewy bodies but not AD.
Neurology. 2001;56(5):643–9.
43. O’Brien JT, Firbank MJ, Davison C, Barnett N,
Bamford C, Donaldson C, et al. 18F-FDG PET and
perfusion SPECT in the diagnosis of Alzheimer and
Lewy body dementias. J Nucl Med.
2014;55(12):1959–65.
44. Bonanni L, Thomas A, Tiraboschi P, Perfetti B,
Varanese S, Onofrj M. EEG comparisons in early
Alzheimer’s disease, dementia with Lewy bodies
and Parkinson’s disease with dementia patients
with a 2-year follow-up. Brain. 2008;131(Pt
3):690–705.
45. Guerreiro R, Ross OA, Kun-Rodrigues C, Hernandez
DG, Orme T, Eicher JD, et al. Investigating the
genetic architecture of dementia with Lewy bodies:
a two-stage genome-wide association study. Lancet
Neurol. 2018;17(1):64–74.
46. Kanemaru K, Kameda N, Yamanouchi H. Decreased
CSF amyloid beta42 and normal tau levels in
dementia with Lewy bodies. Neurology.
2000;54(9):1875–6.
47. Tiraboschi P, Hansen LA, Alford M, Sabbagh MN,
Schoos B, Masliah E, et al. Cholinergic dysfunction
in diseases with Lewy bodies. Neurology.
2000;54(2):407–11.
48. Bhasin M, Rowan E, Edwards K, McKeith I. Cho-
linesterase inhibitors in dementia with Lewy bod-
ies: a comparative analysis. Int J Geriatr Psychiatry.
2007;22(9):890–5.
49. Inc. E. ARICEPT approved in Japan as treatment
for dementia with Lewy bodies. 2014. https://www.
eisai.com/news/news201452.html. Accessed 01
June 2018.
50. Ikeda M, Mori E, Matsuo K, Nakagawa M, Kosaka K.
Donepezil for dementia with Lewy bodies: a ran-
domized, placebo-controlled, confirmatory phase
III trial. Alzheimers Res Ther. 2015;7(1):4.
51. Mori E, Ikeda M, Nakai K, Miyagishi H, Nakagawa
M, Kosaka K. Increased plasma donepezil concen-
tration improves cognitive function in patients
with dementia with Lewy bodies: an exploratory
pharmacokinetic/pharmacodynamic analysis in a
phase 3 randomized controlled trial. J Neurol Sci.
2016;366:184–90.
52. Mori E, Ikeda M, Kosaka K. Donepezil DLBSI.
Donepezil for dementia with Lewy bodies: a ran-
domized, placebo-controlled trial. Ann Neurol.
2012;72(1):41–52.
Neurol Ther (2018) 7:249–263 261
53. Ikeda M, Mori E, Kosaka K, Iseki E, Hashimoto M,
Matsukawa N, et al. Long-term safety and efficacy of
donepezil in patients with dementia with Lewy
bodies: results from a 52-week, open-label, multi-
center extension study. Dement Geriatr Cogn Dis-
ord. 2013;36(3–4):229–41.
54. Cummings J, Lai TJ, Hemrungrojn S, Mohandas E,
Yun Kim S, Nair G, et al. Role of donepezil in the
management of neuropsychiatric symptoms in
Alzheimer’s disease and dementia with Lewy bod-
ies. CNS Neurosci Ther. 2016;22(3):159–66.
55. Mori E, Ikeda M, Nakagawa M, Miyagishi H, Yam-
aguchi H, Kosaka K. Effects of donepezil on
extrapyramidal symptoms in patients with demen-
tia with Lewy bodies: a secondary pooled analysis of
two randomized-controlled and two open-label
long-term extension studies. Dement Geriatr Cogn
Disord. 2015;40(3–4):186–98.
56. McKeith I, Del Ser T, Spano P, Emre M, Wesnes K,
Anand R, et al. Efficacy of rivastigmine in dementia
with Lewy bodies: a randomised, double-blind,
placebo-controlled international study. Lancet.
2000;356(9247):2031–6.
57. FDA. Exelon prescribing information. 2015. https://
www.accessdata.fda.gov/drugsatfda_docs/label/
2015/020823s032,021025s022lbl.pdf. Accessed 01
June 2018.
58. Edwards K, Royall D, Hershey L, Lichter D, Hake A,
Farlow M, et al. Efficacy and safety of galantamine
in patients with dementia with Lewy bodies: a
24-week open-label study. Dement Geriatr Cogn
Disord. 2007;23(6):401–5.
59. Wesnes KA, Aarsland D, Ballard C, Londos E.
Memantine improves attention and episodic
memory in Parkinson’s disease dementia and
dementia with Lewy bodies. Int J Geriatr Psychiatry.
2015;30(1):46–54.
60. Aarsland D, Ballard C, Walker Z, Bostrom F, Alves G,
Kossakowski K, et al. Memantine in patients with
Parkinson’s disease dementia or dementia with
Lewy bodies: a double-blind, placebo-controlled,
multicentre trial. Lancet Neurol. 2009;8(7):613–8.
61. Stubendorff K, Larsson V, Ballard C, Minthon L,
Aarsland D, Londos E. Treatment effect of
memantine on survival in dementia with Lewy
bodies and Parkinson’s disease with dementia: a
prospective study. BMJ Open. 2014;4(7):e005158.
62. Molloy S, McKeith IG, O’Brien JT, Burn DJ. The role
of levodopa in the management of dementia with
Lewy bodies. J Neurol Neurosurg Psychiatry.
2005;76(9):1200–3.
63. Lucetti C, Logi C, Del Dotto P, Berti C, Ceravolo R,
Baldacci F, et al. Levodopa response in dementia
with lewy bodies: a 1-year follow-up study. Parkin-
sonism Relat Disord. 2010;16(8):522–6.
64. Takahashi H, Yoshida K, Sugita T, Higuchi H, Shi-
mizu T. Quetiapine treatment of psychotic symp-
toms and aggressive behavior in patients with
dementia with Lewy bodies: a case series. Prog
Neuropsychopharmacol Biol Psychiatry.
2003;27(3):549–53.
65. Walker Z, Grace J, Overshot R, Satarasinghe S, Swan
A, Katona CL, et al. Olanzapine in dementia with
Lewy bodies: a clinical study. Int J Geriatr Psychia-
try. 1999;14(6):459–66.
66. Cummings JL, Street J, Masterman D, Clark WS.
Efficacy of olanzapine in the treatment of psychosis
in dementia with lewy bodies. Dement Geriatr
Cogn Disord. 2002;13(2):67–73.
67. Lapid MI, Kuntz KM, Mason SS, Aakre JA, Lundt ES,
Kremers W, et al. Efficacy, safety, and tolerability of
armodafinil therapy for hypersomnia associated
with dementia with Lewy bodies: a pilot study.
Dement Geriatr Cogn Disord. 2017;43(5–6):269–80.
68. Connors M, Quinto L, McKeith I, Brodaty H, Allan
L, Bamford C, Thomas A, Taylor J-P, O’Brien J. Non-
pharmacological interventions for Lewy body
dementia: a systematic review. Psychol Med. 2017.
https://doi.org/10.1017/S0033291717003257.
69. Study evaluating intepirdine (RVT-101) on gait and
balance in subjects with dementia. https://
ClinicalTrials.gov/show/NCT02910102. Accessed
01 June 2018.
70. Study evaluating intepirdine (RVT-101) in subjects
with dementia with lewy bodies: the HEADWAY-
DLB Study. https://ClinicalTrials.gov/show/
NCT02669433. Accessed 01 June 2018.
71. Long-Term Extension Study of Intepirdine (RVT-
101) in subjects with dementia with lewy bodies:
HEADWAY-DLB Extension. https://ClinicalTrials.
gov/show/NCT02928445. Accessed 01 June 2018.
72. Open-label study of nelotanserin in lewy body
dementia with visual hallucinations or rem sleep
behavior disorder. https://ClinicalTrials.gov/show/
NCT02871427. Accessed 01 June 2018.
73. Study evaluating nelotanserin for treatment of
visual hallucinations in subjects with lewy body
dementia. https://ClinicalTrials.gov/show/
NCT02640729. Accessed 01 June 2018.
74. Study evaluating nelotanserin for treatment of rem
sleep behavior disorder in subjects with dementia
262 Neurol Ther (2018) 7:249–263
(DLB or PDD). https://ClinicalTrials.gov/show/
NCT02708186. Accessed 01 June 2018.
75. Company ELa. A study of LY3154207 in partici-
pants with parkinson’s disease dementia (PRE-
SENCE). https://www.clinicaltrials.gov/ct2/show/
NCT03305809. Accessed 01 June 2018.
76. Eisai Inc. study to evaluate the efficacy, safety and
tolerability of e2027 in subjects with dementia with
lewy bodies. https://www.clinicaltrials.gov/ct2/
show/NCT03467152. Accessed 01 June 2018.
77. Goldberg NRS, Marsh SE, Ochaba J, Shelley BC,
Davtyan H, Thompson LM, et al. Human neural
progenitor transplantation rescues behavior and
reduces alpha-synuclein in a transgenic model of
dementia with lewy bodies. Stem Cells Transl Med.
2017;6(6):1477–90.
78. Gerard M, Debyser Z, Desender L, Baert J, Brandt I,
Baekelandt V, et al. FK506 binding protein 12 dif-
ferentially accelerates fibril formation of wild type
alpha-synuclein and its clinical mutants A30P or
A53T. J Neurochem. 2008;106(1):121–33.
Neurol Ther (2018) 7:249–263 263
